WO1994024557A1 - Article et procede permettant de detecter la presence de germes pathogenes dans des matieres fecales - Google Patents
Article et procede permettant de detecter la presence de germes pathogenes dans des matieres fecales Download PDFInfo
- Publication number
- WO1994024557A1 WO1994024557A1 PCT/US1994/004073 US9404073W WO9424557A1 WO 1994024557 A1 WO1994024557 A1 WO 1994024557A1 US 9404073 W US9404073 W US 9404073W WO 9424557 A1 WO9424557 A1 WO 9424557A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- detecting means
- excreta
- article
- cytomegalovirus
- substance
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
- G01N33/528—Atypical element structures, e.g. gloves, rods, tampons, toilet paper
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/42—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators with wetness indicator or alarm
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
Definitions
- the present invention addresses that need by providing a means for rapid detection of multiple- pathologies that can be detecting in excreta.
- CMV cytomegalovirus
- Identification of the 90% of CMV-infected infants who are asymptomatic at birth is important to provide promising new treatments to block further viral damage, to implement testing to identify subtle or late damage to these infants, and to fully characterize the epidemiology of infection and transmission of the virus during pregnancy.
- the only method of detecting CMV infection currently in use is culture of urine. This procedure is unsuitable because it requires special handling, is typically expensive and the results are not known for two or three days after a child leaves the newborn nursery.
- This invention provides an article that would be worn by a person for the purpose of indicating potential affliction with pathologies that can be detected in excreta.
- the article comprises a means for detecting the presence of substances associated with such pathologies and a means for carrying the detecting means such that the detecting means can come in contact with the excreta.
- Embodiments of the carrying means include a diaper, a tampon and a feminine hygiene pad.
- the detecting means can either be integrally found on or in the carrying means (as, for example, disposed on the fibrous material of a diaper) or disposed on a substrate that is detachably secured to the carrying means.
- the substrate can be constructed of a non-porous, flexible material, such as plastic, which is in the form of a strip.
- the strip is capable of being placed within a pocket formed on the carrying means so that after it has come in contact with the excreta, the strip can be removed for analysis of the detecting means.
- the detecting means can be an antigen, such as a human virus or an antigen of the virus, or an antibody.
- the virus can be cytomegalovirus (CMV) or human immunodeficiency virus (HIV) .
- CMV cytomegalovirus
- HAV human immunodeficiency virus
- the substance detected can be a protein, glucose, bilirubin, a ketone, hemoglobin, urobilinogen, a nitrite, a leukocyte or a combination thereof.
- Methods of detecting CMV or substances associated with current or previous CMV infection in excreta are also provided.
- a method of diagnosing a subject as potentially afflicted with such pathologies and a method of analyzing the detecting means after it has been in contact with excreta are also provided.
- FIG. 1 is a perspective view of the absorptive side of a disposable diagnostic diaper illustrating a possible location for positioning the detecting means of the present invention on the diaper;
- FIG. 2 is a cross-sectional view of the disposable diagnostic diaper taken along Line 2—2 in FIG. 1;
- FIG. 3 is a cross-sectional view of an alternative embodiment of a diaper illustrating that the detecting means can be interspersed among the fibers of the absorptive portion the diaper;
- FIG. 4 is a perspective view of a substrate of the type that is contained within the retaining means of the diaper in FIG. 1;
- FIG. 5 is a perspective view of a tampon with the detecting means thereon or embedded therein;
- FIG. 6 is a perspective view of an alternative embodiment of a tampon with the detecting means interspersed among the fibers of the absorptive portion the tampon;
- FIG. 7 is a perspective view of a feminine hygiene pad with the detecting means of the present invention therein.
- FIG. 8 is a perspective view of an alternative embodiment of a feminine hygiene pad with the detecting means interspersed among the fibers of the absorptive portion the pad.
- a diaper 10 is shown as a means for carrying the means for detecting at least one substance associated with at least one pathology that can be detected in excreta.
- the diaper 10 may be of the disposable type.
- a retaining means in the form of a pocket or sleeve 12 on the absorptive side 14 of the diaper receives at least one substrate 16 containing thereon, or embedded therein, a detecting means.
- Detecting means would include as many particles, be they enzymes, antibodies or antigens, as would be necessary to detect the substance associated with the pathology being diagnosed.
- the substrate 16 is normally of a flexible construction which would be in fluid communication with the excreta of the user through the pocket 12 which may be constructed of a porous material.
- the pocket 12 may be integrated into the diaper 10, or may be detachably secured thereon.
- the detecting means 18 on a single substrate 16 could be specifically reactive to only one substance associated with a pathology that can be detected in excreta.
- the substrate 16 could have thereon a plurality of detecting means 18 for detecting the presence of a plurality of pathogens.
- a substance "associated with" a pathology can be a metabolite or other chemical not normally found in the type of excreta being tested, or not normally found in the type of excreta being tested in a given concentration that is clinically relevant and not normally found in the excreta of healthy subjects.
- the individual detecting means 18 could be specifically reactive with a selected one of many "substances", including antigens, antibodies, nucleic acids, amino acids, proteins, glucose, bilirubin, ketone bodies, hemoglobin, urobilinogen, nitrites and leukocytes, or any other substance that is associated with a pathology that can be detected in excreta.
- the term “antigen” includes antigenically specific fragments thereof.
- creta is any excretion of waste from an animal body, namely, urine, feces or menstrual discharge.
- the term "reactive" as applied to the present detecting means 18 capable of binding or otherwise associating nonrandomly with a substance.
- Specifically reactive as used herein to describe an antigen or antibody detecting means describes an antigen or antibody that does not react substantially with any pathology associated substance (antibody or antigen, respectively) other than the one specified, e.g. CMV antigen or antibody.
- the detecting means is an enzyme, enzyme substrate or metabolite
- specifically reactive describes an enzyme, enzyme substrate, metabolite etc. that does not substantially stearically associate with or bind to any pathology associated substance (metabolite, enzyme etc.) other than the one specified, e.g. bilirubin, glucose etc.
- Detecting means includes the antigen, antibody, enzyme, or metabolite etc.
- the capturing means can be the specifically reactive detecting means or it can be a reagent capable of binding a class of compounds, such as proteins, which can then be analyzed more specifically.
- the specific reaction could be between an antibody (detecting means 18) bound to the substrate 16 and pathology associated antigens or other antibodies in the excreta.
- the specific reaction can also be between an antigen (detecting means 18) bound to the substrate 16 and pathology associated antibodies in the excreta. It is also possible to use a detecting means, antibody or antigen based, that is specifically reactive with more than one pathology associated substance.
- an antigen enzyme immunoassays such as immunofluorescence assays (IFA) , enzyme linked immunosorbent assays (ELISA) and immunoblotting
- IFA immunofluorescence assays
- ELISA enzyme linked immunosorbent assays
- An ELISA method effective for the detection of the antigen can, for example, be as follows: (1) bind the antibody to the diaper insert; (2) contact the bound antibody with excreta fluid containing the antigen; (3) contact the above with a secondary antibody bound to a detectable moiety (e.g., horseradish peroxidase enzyme or alkaline phosphatase enzyme) ; (4) contact the above with the substrate for the enzyme; (5) contact the above with a color reagent; (6) observe color change.
- the above method can be readily modified to detect pathology associated antibody as well as antigen.
- Example VIII Examples of methods for detecting a an antigen associated with cytomegalovirus is presented in Example VIII.
- One method details the detection of anti-CMV antibody using a modified Western Blot protocol.
- a second method details the detection of CMV itself or a substance associated with CMV infection, after dissociation from the complex formed by the subject's own anti-CMV antibody, using a modified ELISA protocol.
- MAbs monoclonal antibodies
- excreta from the subject is reacted with the antigen bound to a substrate (e.g. an ELISA 96-well plate) .
- a substrate e.g. an ELISA 96-well plate
- Excess fluid is thoroughly washed away.
- a labeled (enzyme-linked, fluorescent, radioactive, etc.) monoclonal antibody is then reacted with the previously reacted antigen-serum antibody complex. The amount of inhibition of monoclonal antibody binding is measured relative to a control (no patient serum antibody) .
- the degree of monoclonal antibody inhibition is a very specific test for a particular variety or strain since it is based on monoclonal antibody binding specificity.
- MAbs can also be used for detection directly in cells by IFA.
- a micro-agglutination test can also be used to detect the presence of the pathology associated substance in the excreta of the subject. Briefly, latex beads (or red blood cells) are coated with the antigen and mixed with a sample of excreta from the subject, such that antibodies in the excreta that are specifically reactive with the antigen crosslink with the antigen, causing agglutination. The agglutinated antigen-antibody complexes form a precipitate, visible with the naked eye or by spectrophotometer. In a modification of the above test, antibodies specifically reactive with the antigen can be bound to the beads and antigen in the excreta thereby detected.
- the antibody can be bound to a solid phase and reacted with the antigen. Thereafter, a secondary labeled antibody is bound to epitopes not recognized by the first antibody and the secondary antibody is detected. Since the present invention provides examples of current or previous pathology associated antigens other methods such as flow cytometry and immunoprecipitation can also be used as detection methods.
- the antigen or antibody can be bound to a solid phase and contacted by a fluid sample of excreta. This sample can be taken directly from the patient or in a partially purified form. In this manner, antibodies specific for the antigen (the primary antibody) will specifically react with the bound antigen. Thereafter, a secondary antibody bound to, or labeled with, a detectable moiety can be added to enhance the detection of the primary antibody.
- the secondary antibody or other ligand which is reactive either specifically with a different epitope of the antigen or nonspecifically with the ligand or reacted antibody, will be selected for its ability to react with multiple sites on the primary antibody. Thus, for example, several molecules of the secondary antibody can react with each primary antibody, making the primary antibody more detectable.
- the detectable moiety will allow visual detection of a precipitate or a color change, visual detection by microscopy, or automated detection by spectrophotometry, radiometric measurement or the like.
- detectable moieties include fluorescein and rhoda ine (for fluorescence microscopy) , horseradish peroxidase (for either light or electron microscopy and biochemical detection) , biotin-streptavidin (for light, electron microscopy or biochemistry) and alkaline phosphatase (for biochemical detection by color change) .
- the detection methods and moieties used can be selected, for example, from the list above or other suitable examples by the standard criteria applied to such selections (Harlow and Lane, 1988) .
- the detecting means 18 on the substrate 16 can be a nucleic acid complimentary to a nucleic acid associated with the pathology.
- the complimentary nucleic acid in excreta will selectively hybridize with the detecting means which can then be analyzed for the presence of the pathology associated nucleic acid.
- Standard nucleic acid detection methods including, but not limited to, polymerase chain reaction (PCR) , restriction fragment length polymorphisms (RFLP) etc. can be applied (Sombrook et al.) to determine the source of the nucleic acid.
- the presence of many substances associated with a plurality of pathologies can be detected through a single exposure to excreta.
- FIG. 3 discloses such an embodiment of a diaper 10 that indicates that the detecting means 18 are interspersed within or on the fibrous material 26 from which the diaper 10 is constructed, rather than being placed on a separate substrate 16.
- FIG. 2 Shown in FIG. 2 is a cross sectional view of the pocket 12 with a substrate 16 in place therein.
- the pocket 12 is shown as enclosing the substrate 16 between two members.
- a porous first member 20 is exposed on one side to the skin of the subject and on the other side to the/lumen 22 of the pocket 12, such that the substrate 16 comes in contact with excreta through the first member 20 which is acting as a passageway for the excreta.
- a second member 24 is exposed on one side to the lumen 22 of the retaining means 12 and the other side to either some layer of the diaper composition or the outer surface of the diaper 10.
- the second member 24 may be comprised of a substance such as a plastic that would be sufficiently translucent, and perhaps even transparent, to act as a window to allow one to view the substrates 16 through the second member 24 from outside the diaper 10.
- FIG. 4 depicts the substrate 16, in the form of a strip, with the plurality of detecting means 18 thereon or embedded therein.
- FIG 5 Another embodiment of the present invention is shown in FIG 5 in which the carrying means is a tampon 28 with a plurality of detecting means 18 contained on or embedded in a substrate 30.
- the substrate 30 can be permanently affixed to the tampon 28 or can be detachably secured thereon, as perhaps with a VELCRO ® attachment.
- FIG. 6 shows another embodiment of the present invention in which the carrying means is a tampon 28 with a plurality of detecting means 18 contained on or embedded in the material of the tampon 28 itself.
- FIG. 7 Shown in FIG. 7 is a further embodiment of the present invention in which the carrying means is a feminine hygiene pad 32.
- a plurality of substrates 16, each having thereon a plurality of detecting means 18 are contained in a retaining means 34, such as a pocket. The substrates 16 can be removed for further analysis.
- FIG. 8 discloses an alternative embodiment in which the carrying means is a feminine hygiene pad 32.
- a plurality of detecting means 18 are shown as being directly on or embedded in the fibers of the pad 32 itself.
- the present invention is used to assess the severity of human ketosis by detecting the presence of ketone bodies in urine.
- the substrate used is a strip impregnated with reagents capable of detecting ketone bodies.
- Sodium nitroprusside, glycine and alkaline phosphate buffers are the primary ingredients.
- a pH of 9 is provided which is optimal for the reaction of nitroprusside with acetoacetic acid and acetone.
- the concentration of nitroprusside is approximately 7 % of the dry weight at time of impregnation.
- Visually assessable positive reactions are uniform and range from bright lavender to bright purple. Ketone results are interpreted as negative, small, moderate or large depending on the resulting color.
- the present invention is used to assess the existence of liver disease, such as viral hepatitis, by detection of even very low concentrations of bilirubin in urine. Normally no bilirubin is detectable in urine by even the most sensitive of methods. Trace amounts in the urine are thus sufficient to warrant further testing.
- liver disease such as viral hepatitis
- the substrate used is a strip to which detecting means (reagents) specifically reactive with bilirubin are affixed.
- the detection is based on the coupling of bilirubin with diazotized dichloroaniline in a strongly acidic medium.
- Reagents include 2,4-dichloroaniline, diazonium salt and buffers.
- the substrate having detecting means thereon is contacted with diazonium salt resulting in the appearance of color. The color ranges through various shades of tan.
- the present invention is used to detect even low concentrations of blood in the urine.
- the significance of trace amounts of blood in the urine may vary between patients but the existence of blood in urine warrants further testing.
- the substrate used is a strip to which specific reagents reactive with hemoglobin or myoglobin are affixed.
- Reagents include 6.8% diisopropyl benzene dihydroperoxide, 4.0% 3,3',5,5' tetromethylbenzidine and 48% buffers.
- the detection is based on the peroxidase- like activity of hemoglobin, which catalyzes the reaction of diisopropylbenzene dihydroperoxide and 3,3' ,5,5'- tetramethylbenzidine.
- the resulting color ranges from orange through green. Further assessment and microscopic inspection may be warranted by the presence of green spots or a uniform green color. Reactions ranging from trace to large, with an equally broad range of occurrence of spots, may be observed.
- Hemoglobin concentration of 0.015-0.062 mg/dl is equivalent to 5-20 intact cells per microliter of urine.
- the sensitivity of this test may be reduced in urine with high specific gravity.
- Proteinuria can be caused by a host of disorders including cardiac disease, intestinal decomposition, persistent fever, hyperthyroidism, or multiple myeloma, but is usually indicative of renal disease or damage.
- the substrate used is a strip to which detecting means specifically reactive with protein are affixed.
- Reagents include 0.3% tetrabromophenol and 97.3% buffers.
- the reagents used would be more sensitive to albumins than globulins.
- the reaction is based on the protein-error-of- indicators principle. That is, at a constant pH, any green color indicates the presence of protein. Colors range from yellow for negative to blue for positive.
- Urobilinogen is a colorless compound formed in the intestines by the reduction of bilirubin. It may be oxidized to urobilin in urine, where high concentrations indicate cirrhosis of the liver.
- the substrate used is a strip to which detecting means specifically reactive with urobilinogen would be affixed.
- the test is based on a modified Ehrlich reaction in which 0.2 % p- diethyla inobenzaldehyde in conjunction with a color enhancer reacts with urobilinogen in a highly acidic medium to form a pink-red color.
- the normal range of urobilinogen concentrations detected with this method is 0.2-1.0 mg/dl (1 mg/dl is approximately equal to one Ehrlich unit/dl) .
- a result of 2.0 mg/dl represents the transition from normal to abnormal.
- the reaction depends on the conversion of nitrate to nitrite by Gram-negative bacteria in the urine.
- the test is, therefore, a reliable predictor of bacteriuria and the attendant urinary tract infection.
- the substrate used would be a strip to which detecting means specifically reactive with nitrite would be affixed.
- nitrite reacts with p-arsanilic acid to form a diazonium compound.
- This compound couples with 1,2,3,4- tetrahydrobenzo(h)-quinolin-3-ol to produce a pink color.
- Reagents include 1.4% p-arsanilic acid, 1.3% 1,2,3,4- tetrahydrobenzo(h)-quinolin-3-ol and 10.8% buffers. Any degree of uniform pink coloration would indicate the presence of 10 5 or more organisms per ml.
- the substrate used is a strip to which detecting means specifically reactive with leukocytes are affixed.
- Reagents include 0.4% derivatized pyrrole amino acid ester, 0.2% diazonium salt and 40.9% buffers.
- the test is based on the principle that leukocytes contain esterases that catalyze the hydrolysis of derivatized pyrrole amino acid ester to liberate 3-hydroxy-5-phenyl pyrrole. This product then reacts with a diazonium salt to produce a purple product.
- Dissociation of the CMV-antibody complex that may exist in urine is accomplished by adding .12 M hydrochloric acid (HCl) to the urine sample and incubating for 30 min. The urine is then neutralized to pH 7 using .5M HEPES buffer.
- HCl hydrochloric acid
- ELISA Plates are coated overnight at 4°C with lOO ⁇ l of 1:400 dilution of CMV-Ig that had been prepared from serum of an immunized goat by ammoniumsulphate precipitation and affinity purification. All incubations are done for 1 h at 37°C, and the plates are washed between each step with phosphate buffered saline solution with 0.05% Tween 20, pH 7.4 (PBSST) .
- PBSST phosphate buffered saline solution with 0.05% Tween 20, pH 7.4
- the plates are incubated with 5% milk in PBSS, dissociated antigen in 40 mM HEPES buffer with 5% milk (HM) , a 1:3000 dilution of two monoclonal antibodies to a late CMV antigen (MAB8125 and 8126, Chemicon Int., Temecula, CA) in HM, alkaline phosphatase labelled rabbit- anti-mouse Ig (Tago, Burlinghame, CA) in HM, and the enzyme substrate.
- This method can detect CMV present in urine.
- Virus specificity of the WB results is tested by blocking assays, in which the urine or serum samples are incubated before the actual WB assay with a predetermined concentration of cell culture-grown CMV (ATCC No. ATCCL136 VR538) , HHV6, or the respective uninfected cell lysates as controls.
- a predetermined concentration of cell culture-grown CMV ATCC No. ATCCL136 VR538
- HHV6 the respective uninfected cell lysates as controls.
- the samples are preincubated with serum from a CMV-seronegative individual or with a high concentration of purified B2m.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Article et procédé indiquant la présence potentielle d'états pathologiques pouvant être détectés dans les matières fécales. L'article comprend un moyen de détection de la présence de substances associées à de tels états, ainsi qu'un moyen permettant à un sujet de porter le moyen de détection de façon que ce dernier entre en contact avec les matières fécales. Des procédés permettant de détecter une infection par des cytomégalovirus dans les matières fécales sont également décrits.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU67042/94A AU6704294A (en) | 1993-04-16 | 1994-04-13 | Article and method for detecting the presence of pathogens in excreta |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4880793A | 1993-04-16 | 1993-04-16 | |
US08/048,807 | 1993-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994024557A1 true WO1994024557A1 (fr) | 1994-10-27 |
Family
ID=21956559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/004073 WO1994024557A1 (fr) | 1993-04-16 | 1994-04-13 | Article et procede permettant de detecter la presence de germes pathogenes dans des matieres fecales |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6704294A (fr) |
WO (1) | WO1994024557A1 (fr) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000000233A1 (fr) * | 1998-06-29 | 2000-01-06 | The Procter & Gamble Company | Article jetable avec detecteur de dejections |
WO2000025836A1 (fr) * | 1998-10-29 | 2000-05-11 | The Procter & Gamble Company | Articles hygieniques contenant des capteurs pour matieres fecales |
WO2000065084A2 (fr) * | 1999-04-26 | 2000-11-02 | The Procter & Gamble Company | Composition pour detection de sang |
FR2793883A1 (fr) * | 1999-05-19 | 2000-11-24 | Hemery Fernand Moutete | Dispositif de recueil et d'analyse des secretions corporelles de la region urogenitale |
WO2001013109A2 (fr) * | 1999-08-12 | 2001-02-22 | Gael Michael R | Dispositif comprenant des reactifs utilise pour detecter des etats pathologiques |
WO2001054642A2 (fr) * | 2000-01-24 | 2001-08-02 | Buzluhan Huelya | Protege-slip pour femmes, en particulier pour femmes enceintes |
WO2001072252A1 (fr) * | 2000-03-25 | 2001-10-04 | The Procter & Gamble Company | Article absorbant transparent |
WO2008132620A2 (fr) * | 2007-04-30 | 2008-11-06 | Kimberly-Clark Worldwide, Inc. | Dispositif à écoulement latéral pour une fixation à un article absorbant |
US7982088B2 (en) | 1998-06-29 | 2011-07-19 | The Procter & Gamble Company | Disposable article having a biosensor |
US8053625B2 (en) | 2006-12-14 | 2011-11-08 | Kimberly-Clark Worldwide, Inc. | Absorbent articles including a body fluid signaling device |
EP2518506A3 (fr) * | 2004-10-22 | 2012-11-21 | Kimberly-Clark Worldwide, Inc. | Détection de trichomonas |
US9131893B2 (en) | 2012-10-26 | 2015-09-15 | Pixie Scientific, Llc | Health diagnostic systems and methods |
WO2015187073A1 (fr) * | 2014-06-05 | 2015-12-10 | Sca Hygiene Products Ab | Agencement de test de fluide corporel pour un article absorbant |
US9486368B2 (en) | 2013-12-05 | 2016-11-08 | Medline Industries, Inc. | Disposable hygienic article with means for diagnostic testing |
US10383564B2 (en) | 2015-05-22 | 2019-08-20 | Pixie Scientific, Llc | Indicator panels for incontinence products |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE642811A (fr) * | 1963-01-23 | 1964-05-15 | ||
GB2022423A (en) * | 1978-07-07 | 1979-12-19 | Super Iride Spa | Improvements in and relating to sanitary clothing |
EP0101980A2 (fr) * | 1982-08-23 | 1984-03-07 | Eisai Co., Ltd. | Procédé de fabrication d'un dispositif diagnostique |
EP0467175A2 (fr) * | 1990-07-17 | 1992-01-22 | Roche Diagnostics GmbH | Trousse pour la détermination d'une analyte dans un échantillon semi-solide, en particulier dans les selles |
WO1992008809A1 (fr) * | 1990-11-19 | 1992-05-29 | University Of Florida | Dispositif et procede de dosage pour la detection d'anticorps et d'antigenes |
JPH04232854A (ja) * | 1990-12-28 | 1992-08-21 | Japan Vilene Co Ltd | 尿検査用呈色試薬収容体 |
EP0510195A1 (fr) * | 1989-12-25 | 1992-10-28 | Daiki Co., Ltd | Feuille, siege, sac ou article d'usage quotidien, encre et materiau de revetement de surface pour animaux |
-
1994
- 1994-04-13 WO PCT/US1994/004073 patent/WO1994024557A1/fr active Application Filing
- 1994-04-13 AU AU67042/94A patent/AU6704294A/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE642811A (fr) * | 1963-01-23 | 1964-05-15 | ||
GB2022423A (en) * | 1978-07-07 | 1979-12-19 | Super Iride Spa | Improvements in and relating to sanitary clothing |
EP0101980A2 (fr) * | 1982-08-23 | 1984-03-07 | Eisai Co., Ltd. | Procédé de fabrication d'un dispositif diagnostique |
EP0510195A1 (fr) * | 1989-12-25 | 1992-10-28 | Daiki Co., Ltd | Feuille, siege, sac ou article d'usage quotidien, encre et materiau de revetement de surface pour animaux |
EP0467175A2 (fr) * | 1990-07-17 | 1992-01-22 | Roche Diagnostics GmbH | Trousse pour la détermination d'une analyte dans un échantillon semi-solide, en particulier dans les selles |
WO1992008809A1 (fr) * | 1990-11-19 | 1992-05-29 | University Of Florida | Dispositif et procede de dosage pour la detection d'anticorps et d'antigenes |
JPH04232854A (ja) * | 1990-12-28 | 1992-08-21 | Japan Vilene Co Ltd | 尿検査用呈色試薬収容体 |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Week 9240, Derwent World Patents Index; AN 92-327103 * |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7982088B2 (en) | 1998-06-29 | 2011-07-19 | The Procter & Gamble Company | Disposable article having a biosensor |
WO2000000233A1 (fr) * | 1998-06-29 | 2000-01-06 | The Procter & Gamble Company | Article jetable avec detecteur de dejections |
WO2000025836A1 (fr) * | 1998-10-29 | 2000-05-11 | The Procter & Gamble Company | Articles hygieniques contenant des capteurs pour matieres fecales |
WO2000065348A3 (fr) * | 1999-04-26 | 2001-04-05 | Procter & Gamble | Articles jetables et analogues comprenant un dispositif de detection |
WO2000065096A1 (fr) * | 1999-04-26 | 2000-11-02 | The Procter & Gamble Company | Protege-slip dote de capteur conçu pour predire le debut de la menstruation |
WO2000065347A2 (fr) * | 1999-04-26 | 2000-11-02 | The Procter & Gamble Company | Dispositif pour diagnostics multiples de la sante de la femme |
WO2000065348A2 (fr) * | 1999-04-26 | 2000-11-02 | The Procter & Gamble Company | Articles jetables et analogues comprenant un dispositif de detection |
WO2000065083A3 (fr) * | 1999-04-26 | 2001-02-08 | Procter & Gamble | Protections periodiques feminines jetables pourvues d'un moyen de detection du sang, en tant que capteur |
WO2000065347A3 (fr) * | 1999-04-26 | 2001-03-01 | Procter & Gamble | Dispositif pour diagnostics multiples de la sante de la femme |
WO2000065084A3 (fr) * | 1999-04-26 | 2001-04-12 | Procter & Gamble | Composition pour detection de sang |
WO2000065083A2 (fr) * | 1999-04-26 | 2000-11-02 | The Procter & Gamble Company | Protections periodiques feminines jetables pourvues d'un moyen de detection du sang, en tant que capteur |
WO2000065084A2 (fr) * | 1999-04-26 | 2000-11-02 | The Procter & Gamble Company | Composition pour detection de sang |
FR2793883A1 (fr) * | 1999-05-19 | 2000-11-24 | Hemery Fernand Moutete | Dispositif de recueil et d'analyse des secretions corporelles de la region urogenitale |
WO2000072009A1 (fr) * | 1999-05-19 | 2000-11-30 | Hemery Fernand Moutete | Dispositif de recueil et d'analyse des secretions corporelles |
WO2001013109A2 (fr) * | 1999-08-12 | 2001-02-22 | Gael Michael R | Dispositif comprenant des reactifs utilise pour detecter des etats pathologiques |
WO2001013109A3 (fr) * | 1999-08-12 | 2001-11-22 | Michael R Gael | Dispositif comprenant des reactifs utilise pour detecter des etats pathologiques |
WO2001054642A3 (fr) * | 2000-01-24 | 2001-12-20 | Huelya Buzluhan | Protege-slip pour femmes, en particulier pour femmes enceintes |
US6982360B2 (en) | 2000-01-24 | 2006-01-03 | Buzluhan Huelya | Pantyliner for women, in particular for pregnant women |
WO2001054642A2 (fr) * | 2000-01-24 | 2001-08-02 | Buzluhan Huelya | Protege-slip pour femmes, en particulier pour femmes enceintes |
EP1138293A1 (fr) * | 2000-03-25 | 2001-10-04 | The Procter & Gamble Company | Article absorbant transparent |
WO2001072252A1 (fr) * | 2000-03-25 | 2001-10-04 | The Procter & Gamble Company | Article absorbant transparent |
JP2003527928A (ja) * | 2000-03-25 | 2003-09-24 | ザ、プロクター、エンド、ギャンブル、カンパニー | 透明な吸収性物品 |
KR100728399B1 (ko) * | 2000-03-25 | 2007-06-13 | 더 프록터 앤드 갬블 캄파니 | 투명한 흡수 제품 |
US8491554B2 (en) | 2000-03-25 | 2013-07-23 | The Procter And Gamble Company | Transparent absorbing article |
EP2518506A3 (fr) * | 2004-10-22 | 2012-11-21 | Kimberly-Clark Worldwide, Inc. | Détection de trichomonas |
US8053625B2 (en) | 2006-12-14 | 2011-11-08 | Kimberly-Clark Worldwide, Inc. | Absorbent articles including a body fluid signaling device |
WO2008132620A3 (fr) * | 2007-04-30 | 2008-12-31 | Kimberly Clark Co | Dispositif à écoulement latéral pour une fixation à un article absorbant |
WO2008132620A2 (fr) * | 2007-04-30 | 2008-11-06 | Kimberly-Clark Worldwide, Inc. | Dispositif à écoulement latéral pour une fixation à un article absorbant |
US9895094B2 (en) | 2007-04-30 | 2018-02-20 | Kimberly-Clark Worldwide, Inc. | Lateral flow device for attachment to an absorbent article |
US9131893B2 (en) | 2012-10-26 | 2015-09-15 | Pixie Scientific, Llc | Health diagnostic systems and methods |
US10251602B2 (en) | 2012-10-26 | 2019-04-09 | Pixie Scientific, Llc | Health diagnostic systems and methods |
US9486368B2 (en) | 2013-12-05 | 2016-11-08 | Medline Industries, Inc. | Disposable hygienic article with means for diagnostic testing |
US10583047B2 (en) | 2013-12-05 | 2020-03-10 | Medline Industries, Inc. | Disposable hygienic article with means for diagnostic testing |
US11376166B2 (en) | 2013-12-05 | 2022-07-05 | Medline Industries, Lp | Disposable hygienic article with means for diagnostic testing |
WO2015187073A1 (fr) * | 2014-06-05 | 2015-12-10 | Sca Hygiene Products Ab | Agencement de test de fluide corporel pour un article absorbant |
US10383564B2 (en) | 2015-05-22 | 2019-08-20 | Pixie Scientific, Llc | Indicator panels for incontinence products |
Also Published As
Publication number | Publication date |
---|---|
AU6704294A (en) | 1994-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005210742B2 (en) | Method for the rapid diagnosis of targets in human body fluids | |
WO1994024557A1 (fr) | Article et procede permettant de detecter la presence de germes pathogenes dans des matieres fecales | |
US5910421A (en) | Rapid diagnostic method for distinguishing allergies and infections | |
US6967084B2 (en) | Kit for rapidly diagnosing upper respiratory conditions | |
US5051356A (en) | Specific binding composition comprising a low pI protein or carbohydrate and a diagnostic test kit and method of use | |
AU2002248996B2 (en) | Detection of candida | |
DK174032B1 (da) | Sæt samt fremgangsmåde til immunometrisk dosering, der kan anvendes på hele celler | |
CA2230644A1 (fr) | Procede d'elimination de l'interference du facteur rhumatoide dans les dosages diagnostiques | |
AU774699B2 (en) | Devices and methods for the detection and identification of crystals in biological fluids | |
US20110065139A1 (en) | diagnostic device for identifying rupture of membrane during pregnancy | |
US20130177485A1 (en) | Diagnostic device for identifying rupture of membrane during pregnancy | |
AU2008313294A1 (en) | A diagnostic device for identifying rupture of membrane during pregnancy | |
Holland et al. | A comparison of chemical dipsticks read visually or by photometry in the routine screening of urine specimens in the clinical microbiology laboratory | |
MXPA01009304A (es) | Metodos de diagnostico rapido para alergias e infecciones distintivas. | |
Peredy et al. | Bedside diagnostic testing of body fluids | |
AU779524B2 (en) | Assay | |
Molyneux et al. | A dipstick test for urinary tract infections. | |
Rasmussen et al. | Evaluation and quality control of a monoclonal antibody based enzyme antigen immunoassay of acetylcholinesterase in amniotic fluid | |
JP2571383B2 (ja) | 生体成分中のヒト・ヘモグロビンの測定方法及び測定用試薬キット | |
PL239791B1 (pl) | Test paskowy do wykrywania enzootycznej białaczki bydła i sposób wykrywania enzootycznej białaczki bydła z wykorzystaniem tego testu paskowego | |
Laze et al. | Preliminary evaluation of Chorus System in comparison with mini-vidas system for detection of cytomegalovirus-IgM antibodies | |
STANDARD | Legionella Ag FIA | |
CA2745309A1 (fr) | Dispositif diagnostic pour identifier la rupture de la membrane pendant la grossesse | |
Singh et al. | INCIDENCE AND PREVALENCE OF TOXOPLASMOSIS IN PREGNANT WOMEN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |